Hormone replacement therapy has become one of the most debated topics in healthy aging.

One side of the conversation can make hormones sound dangerous and something that should be avoided whenever possible. The other can make estrogen, progesterone or testosterone sound like anti-aging compounds that nearly everyone should be taking.

Neither extreme captures the reality.

Hormone therapy is medicine. Like any medical treatment, it has appropriate uses, potential benefits, contraindications, side effects and situations where the answer is less obvious.

The first question therefore should not be:

“How high can I get my hormones?”

It should be:

“What problem are we trying to treat, and does hormone therapy offer more benefit than risk for this individual?”

Think About HRT Like a Traffic Light

A useful way to think about hormone therapy is with three categories: green, yellow and red.

The traffic-light concept is useful because many patients do not fall neatly into “yes” or “no.”

Someone may have significant menopause symptoms but also obesity, high blood pressure or high triglycerides. Another person may have low testosterone symptoms but untreated severe sleep apnea or an elevated hematocrit.

These situations call for evaluation—not automatic treatment and not automatic rejection.

When Menopausal Hormone Therapy Can Be Very Effective

For women experiencing significant menopause symptoms, hormone therapy can provide substantial relief.

Common symptoms include:

• Hot flashes
• Night sweats
• Sleep disruption related to vasomotor symptoms
• Vaginal dryness
• Pain during intercourse
• Genitourinary symptoms related to menopause

ACOG describes systemic estrogen therapy, with or without a progestogen depending on the patient, as the most effective treatment for hot flashes and night sweats.

Systemic estrogen also helps protect against the accelerated bone loss that occurs around menopause.

The Menopause Society notes that for many women with bothersome symptoms, the benefit-risk balance is particularly favorable when treatment begins before age 60 or within approximately 10 years of menopause onset, assuming no major contraindications.

Sources: ACOG hormone therapy guidance and The Menopause Society.

Estrogen Alone vs. Estrogen Plus Progesterone

One of the most important factors in menopausal hormone therapy is whether the patient still has a uterus.

Systemic estrogen stimulates the lining of the uterus. If someone with an intact uterus takes systemic estrogen without adequate endometrial protection, the risk of endometrial hyperplasia and endometrial cancer increases.

That is why women who still have a uterus generally receive a progestogen along with systemic estrogen.

Low-dose vaginal estrogen is different from systemic hormone therapy. It delivers medication primarily to vaginal tissues, with very little entering the bloodstream compared with systemic therapy.

This is why treatment can often be tailored to the symptom rather than automatically giving a full systemic hormone regimen.

The Route Matters: Oral Estrogen vs. Patches and Gels

Not every estrogen formulation has exactly the same risk profile.

Oral estrogen passes through the liver before reaching the systemic circulation. Transdermal estrogen—such as a patch, gel or spray—is absorbed through the skin and avoids much of this first-pass liver exposure.

This distinction can matter in patients with concerns such as:

• Elevated triglycerides
• Obesity
• Blood-clot risk factors
• Cardiovascular risk
• Gallbladder concerns

ACOG notes that patches, sprays and rings may have a lower risk of deep-vein thrombosis than estrogen taken by mouth.

This does not mean transdermal therapy is risk-free. It means the route can be one of the tools a clinician uses to improve the risk-benefit equation.

FDA Updated Menopause Hormone Labels in 2026

The regulatory discussion around menopausal hormone therapy also changed recently.

In February 2026, FDA approved labeling changes for an initial group of menopausal hormone therapy products that removed boxed-warning statements related to cardiovascular disease, breast cancer and probable dementia.

The change followed a review of newer evidence and was intended to better reflect differences in patient age, timing, formulation and treatment circumstances.

That update should not be interpreted as saying hormone therapy has no risks.

Current professional guidance still recommends individualized assessment of factors such as:

• Age
• Years since menopause
• Breast and endometrial cancer history
• History of blood clots
• Stroke or heart attack history
• Liver disease
• Cardiovascular risk factors
• The type and route of hormone therapy

Source: FDA 2026 menopausal hormone therapy labeling update.

Testosterone Therapy for Men: Treat the Patient, Not Just the Number

Men’s hormone therapy creates a similar problem: testosterone levels can be interpreted too simplistically.

A single testosterone result of 300, 350 or 400 ng/dL does not automatically answer whether a man should begin TRT.

Current Endocrine Society guidance emphasizes both clinical symptoms and consistently low testosterone measurements.

Symptoms that may prompt evaluation include:

• Reduced libido
• Erectile or sexual symptoms
• Reduced spontaneous erections
• Reduced muscle mass or strength
• Unexplained anemia
• Low energy in the appropriate clinical context

Because testosterone concentrations fluctuate, diagnosis typically involves repeat morning testing using accurate laboratory methods.

The clinician may also evaluate why testosterone is low rather than immediately replacing it.

Potential contributors can include obesity, certain medications, pituitary disorders, testicular disease, severe illness and sleep problems.

Source: Endocrine Society testosterone therapy guideline.

Is Testosterone Heart-Protective?

Testosterone should not be started simply as a drug to prevent heart disease.

The large TRAVERSE trial helped answer an important safety question. More than 5,200 men between ages 45 and 80 with hypogonadism and existing cardiovascular disease or elevated cardiovascular risk were randomized to testosterone gel or placebo.

Major adverse cardiovascular events occurred in:

The study found testosterone was noninferior to placebo for the primary cardiovascular safety outcome.

That is reassuring for appropriately selected men with confirmed hypogonadism.

But “not more cardiovascular events than placebo” is not the same thing as proving TRT prevents heart attacks.

The study also reported higher incidences of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group, reinforcing the need for individualized monitoring.

FDA has also required testosterone product labeling to address possible increases in blood pressure.

Sources: TRAVERSE cardiovascular safety trial and FDA testosterone information.

The Yellow-Light Patient: Cardiovascular and Metabolic Risk

Hormone therapy decisions become more complicated when someone also has significant cardiovascular or metabolic disease.

Examples include:

• Obesity
• Diabetes or insulin resistance
• Uncontrolled high blood pressure
• High triglycerides
• Sleep apnea
• Smoking
• Known vascular disease
• Elevated cardiovascular risk

These factors do not always mean hormone therapy is impossible.

They mean the underlying conditions should be treated rather than expecting hormones to substitute for cardiovascular prevention, nutrition, weight management, exercise or sleep treatment.

A clinician may choose a different route, use a lower effective dose, obtain additional evaluation or delay treatment while a higher-priority problem is addressed.

For example, someone with untreated sleep apnea should not assume fatigue is purely a testosterone problem.

Someone with poorly controlled hypertension should not expect estrogen or testosterone to fix the blood pressure.

And hormone therapy should not be treated as a weight-loss medication.

What About Testosterone Therapy for Women?

Testosterone is increasingly discussed in menopause and longevity clinics, but this area requires careful terminology.

As of 2026, there is no FDA-approved testosterone formulation specifically for women in the United States.

That does not mean testosterone has no evidence-based role.

Clinical guidelines support consideration of systemic transdermal testosterone for carefully selected postmenopausal women with hypoactive sexual desire disorder, or HSDD, after a proper biopsychosocial assessment and discussion of benefits, risks and off-label use.

The evidence does not support using testosterone in women simply for:

• General anti-aging
• Weight loss
• Building large amounts of muscle
• Improving cognition
• Improving bone health
• Increasing energy in anyone who feels tired

When testosterone is used for HSDD, guidelines recommend keeping levels within the normal physiologic premenopausal female range rather than creating supraphysiologic levels.

Potential androgenic side effects can include acne, increased facial or body hair and, at excessive exposure, potentially irreversible virilizing effects.

Sources: 2025 review of testosterone for HSDD and ACOG clinical consensus.

Cancer History Can Turn a Green Light Yellow—or Red

Cancer risk cannot be reduced to a simple statement that hormones either cause cancer or never affect cancer risk.

The patient’s history matters.

Examples that require particular attention include:

• Personal history of breast cancer
• Personal history of endometrial cancer
• Known hormone-sensitive cancer
• Strong family cancer history
• High-risk genetic mutations
• Abnormal or unexplained uterine bleeding

ACOG states that systemic menopausal hormone therapy usually is not recommended in people who have had breast or endometrial cancer.

A strong family history is not the same thing as personally having hormone-sensitive breast cancer. A genetic predisposition is not the same thing as active cancer.

Those distinctions are why shared decision-making matters.

In a patient with a previous estrogen-receptor-positive breast cancer, decisions about hormonal treatment may require involvement from the oncology team rather than a stand-alone anti-aging clinic.

Who Usually Should Not Start Systemic Menopause Hormone Therapy?

ACOG states that systemic hormone therapy usually is not recommended for people with a history of:

• Breast cancer
• Endometrial cancer
• Stroke
• Heart attack
• Blood clots
• Liver disease

Pregnancy is also incompatible with menopausal hormone therapy.

These are not situations for self-treatment or ordering hormones online because a laboratory number looks low.

Specialist input may sometimes change the available options, particularly when local vaginal therapy is being considered for severe genitourinary symptoms, but systemic treatment requires careful evaluation.

When TRT for Men Needs Extra Caution

The Endocrine Society recommends against starting testosterone therapy in several circumstances, including:

• Planning fertility in the near future
• Breast or prostate cancer
• Elevated hematocrit
• Untreated severe obstructive sleep apnea
• Uncontrolled heart failure
• Recent myocardial infarction or stroke
• Thrombophilia
• Certain concerning prostate findings until further evaluation

Testosterone can suppress sperm production, so fertility deserves discussion before treatment begins.

It can also increase hematocrit, which is why complete blood count monitoring is commonly part of TRT follow-up.

Sleep apnea is another reason not to assume every low-energy symptom requires more testosterone. If poor sleep is the primary problem, treating the sleep disorder may produce far more meaningful improvement.

Hormone Therapy Is Not a Weight-Loss Drug or Gym Membership

One of the most useful principles in healthy aging is understanding what hormone therapy cannot replace.

Hormones do not replace:

• Resistance training
• Adequate protein intake
• Healthy body composition
• Blood-pressure control
• Diabetes treatment
• Sleep apnea treatment
• A nutritious dietary pattern
• Cardiovascular risk management

Someone can have a perfectly managed testosterone prescription and still lose muscle if they never challenge their muscles.

A menopausal woman can use an estrogen patch and still develop metabolic disease if the underlying lifestyle and medical risk factors are ignored.

Hormone therapy may help someone feel better enough to become more active, sleep better or improve sexual function, but it is one tool—not the entire toolbox.

Do You Need a Huge Hormone Panel Before Starting HRT?

Not always.

For typical menopause symptoms, treatment decisions are often based primarily on age, menstrual history, symptoms and medical risk rather than repeatedly chasing estradiol or progesterone laboratory targets.

Hormone concentrations fluctuate significantly during perimenopause, so a single measurement can be misleading.

Testing becomes more useful when the diagnosis is uncertain, another endocrine disorder is suspected or the clinician is evaluating a specific problem.

Testosterone evaluation in men is different because confirming consistently low testosterone is part of diagnosing hypogonadism.

This is another reason there is no single “HRT blood panel” that makes sense for every patient.

Starting Hormone Therapy Is the Beginning of the Process

Hormone therapy should not look like:

“Here is your prescription. See you again in five years.”

Follow-up should assess whether the treatment is actually solving the intended problem and whether new concerns have developed.

Depending on the therapy, monitoring can include:

• Symptom improvement
• Side effects
• Blood pressure
• Abnormal vaginal bleeding
• Testosterone levels when clinically relevant
• Hematocrit in men receiving TRT
• Prostate-related monitoring when indicated
• Signs of androgen excess in women receiving testosterone
• Changes in cardiovascular or metabolic health
• Whether the indication for treatment still exists

Many clinicians reassess patients within the first few months after initiation or a meaningful dose change and continue periodic follow-up thereafter.

The goal is generally to use an effective treatment that addresses the patient’s symptoms without creating unnecessary exposure.

FDA-Approved vs. Compounded “Bioidentical” Hormones

The term bioidentical can be confusing because it is frequently used as a marketing term.

FDA-approved estradiol and micronized progesterone products already exist that are chemically identical to hormones produced by the human body.

A product therefore does not have to be custom compounded to be “bioidentical.”

ACOG recommends FDA-approved menopausal hormone products over compounded products when an appropriate FDA-approved option exists.

Compounded preparations can have legitimate uses—for example, when a patient needs a formulation that is not commercially available or cannot tolerate an ingredient in an approved product.

But custom compounding introduces additional uncertainty around:

• Potency
• Consistency
• Absorption
• Purity
• Quality control
• Long-term safety data

ACOG also advises against routinely using testosterone pellets because they cannot be easily removed once implanted and can produce supraphysiologic levels.

Source: ACOG Compounded Bioidentical Menopausal Hormone Therapy Clinical Consensus.

Questions to Ask Before Starting Hormone Therapy

Frequently Asked Questions

Final Thoughts

Hormone therapy can be an extremely valuable treatment.

It can also be the wrong treatment for the wrong patient.

The mistake is turning hormone therapy into a philosophy where hormones are either always dangerous or where everyone should have their testosterone, estrogen or other hormone pushed toward the top of a laboratory range.

Good hormone management begins with a specific goal.

For a menopausal woman, that goal may be reducing severe hot flashes, improving sleep disrupted by night sweats, treating vaginal symptoms or protecting bone in an appropriate clinical situation.

For a man with hypogonadism, it may be treating clinically meaningful symptoms in the presence of consistently low testosterone.

From there, the clinician has to look at the whole person: cardiovascular health, metabolic disease, sleep, blood pressure, cancer history, fertility, medications, route of administration and treatment risks.

Then the therapy has to be monitored.

Hormones should support health and function—not become a substitute for the rest of health.

Protein still matters. Resistance training still matters. Sleep still matters. Blood pressure, body composition, metabolic health and cancer screening still matter.

Hormone therapy is one tool in the healthy-aging toolbox.

The right question is not whether everyone should use it.

The right question is whether it is the right tool for you.

Video Summary

Disclaimer: This content is for educational purposes and does not replace personalized medical advice.

For more evidence-based nutrition and fitness tips, subscribe to our channel:
https://www.youtube.com/@Vitality-and-Wellness

Looking for extra help with your fitness goals? Check out the personalized Nutrition Program at Parkway Athletic Club:
parkwayathleticclub.com/nutrition